Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 106, Issue 5, Pages 549-556Publisher
WILEY
DOI: 10.1002/jso.23119
Keywords
adrenal neoplasm; adrenocortical carcinoma; genomics; diagnosis; miRNA; mRNA; epigenetics; methylation; CGH
Funding
- Intramural NIH HHS [ZIA BC011275] Funding Source: Medline
Ask authors/readers for more resources
Adrenocortical tumors are common and incidentally discovered in up to 14% of axial imaging studies performed for other indications. Most of these tumors are nonfunctioning but may require removal because of the risk of adrenocortical carcinoma. Unfortunately, most clinical and imaging features are still not accurate enough to allow definitive diagnosis and an increasing number of patients undergo adrenalectomy to exclude a cancer diagnosis. Adrenocortical carcinoma is an aggressive malignancy with no effective therapy for patients with locally advanced and metastatic disease. Studies using new genomic approaches including mRNA, miRNA, methylation, and CGH profiling have identified dysregulated genes and pathways that may have clinical implications in improved molecular diagnosis and prognostication of adrenocortical cancer (ACC). In this review, we highlight recent advances in the molecular diagnosis of adrenocortical tumors. Published 2012. J. Surg. Oncol. 2012; 106:549556. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available